Navigation Links
HIV integrase inhibitor effective for patients beginning antiretroviral treatment
Date:8/2/2009

A member of a new class of antiretroviral drugs is safe and effective for patients beginning treatment against HIV, according to researchers who have completed a two-year multisite phase III clinical trial comparing it with standard antiretroviral drugs.

The results are online and scheduled for publication in an upcoming issue of the Lancet.

Lead author of the Lancet article is Jeffrey Lennox, MD, professor of medicine (infectious diseases) at Emory University School of Medicine. Lennox is chief of Emory's HIV/AIDS clinical trials unit and vice-chair of medicine dealing with Grady Memorial Hospital.

"These results provide an additional potent, well tolerated treatment option for newly diagnosed patients with HIV infection," says Lennox.

Raltegravir, a HIV integrase inhibitor, is overall as effective as widely used efavirenz, a reverse transcriptase inhibitor, the researchers found. Raltegravir also had faster onset of action and fewer adverse side effects. In the clinical trial, both were combined with two other standard retroviral drugs, tenofovir and emtricitabine.

The trial included 566 patients from 67 medical centers on five continents. The "primary endpoint" of the trial was pushing viral levels below 50 copies per ml of blood by week 48. Of the raltegravir group, 86 percent reached that goal, compared with 82 percent of the efavirenz group.

Half the raltegravir group reached the endpoint by week four, compared with less than 20 percent for the efavirenz group. In addition, the raltegravir group encountered fewer side effects such as headache, dizziness and elevation in levels of cholesterol.

Raltegravir inhibits the HIV integrase enzyme, which inserts the viral genome into the host cell's DNA. It was the first integrase inhibitor to be approved by the FDA. Other types of antiretroviral drugs inhibit HIV's protease or reverse transcriptase enzymes.

Guidelines from the U.S. Department of Health and Human Services currently recommend efavirenz or a protease inhibitor, in combination with tenofovir and emtricitabine, as a preferred drug regimen for adults beginning antiretroviral treatment.

Efavirenz, tenofovir and emtricitabine make up a once-a-day combination (Atripla) approved by the FDA in 2006. The authors note that raltegravir is usually taken twice a day, which may be more difficult for some patients. However, raltegravir's reduction in side effects and concerns about the ability of efavirenz to cause birth defects may be advantages for raltegravir, the authors say.

Raltetravir was approved by the FDA in 2007, but at first only for people infected with HIV that is resistant to other drugs. The results of this study contributed to the July 2009 decision by the FDA to expand the indication for raltegravir beyond only individuals infected with HIV that is resistant to other drugs.


'/>"/>

Contact: Sarah Goodwin
sgoodwi@emory.edu
404-727-3366
Emory University
Source:Eurekalert

Related medicine news :

1. Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
3. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
4. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
5. Silencing small but mighty cancer inhibitors
6. S*BIOs Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders
7. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
8. Effect of tumor necrosis factor a inhibitors on heart failure risk in RA Patients
9. Late Use of Aromatase Inhibitor Still Effective Against Breast Cancer
10. NSAIDs: Painkillers, inflammation inhibitors, anti-cancer drugs and new de-methylating agents
11. ACE Inhibitor as Effective as More Expensive Blood Pressure Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... "Add realistic flares and light ... and flare from clip to clip with high quality 4K lens flare footage," said ... contains 44 lens flares filmed on the RED Dragon. Utilizing the Dragon Sensor, TransFlare ...
(Date:12/5/2016)... ... December 05, 2016 , ... What: Shriners Hospitals for ... North Pole to our patients – using a video monitor and web-enabled camera. Santa ... will transform the Auditorium into a Christmas Wonderland, which is where the video connection ...
(Date:12/5/2016)... ... December 05, 2016 , ... Edward ... to announce the arrival of the newest Sciton laser in January 2017. The ... use tunable non-ablative and ablative wavelengths for exceptional results. Outperforming more traditional lasers, ...
(Date:12/5/2016)... Ill. (PRWEB) , ... December 06, 2016 , ... For ... Lithuanian poetry , both thick and thin. The beauty of the Lithuanian ... by Trafford Publishing). , In this poetry book, Zubinas lyrically explores all aspects of ...
(Date:12/5/2016)... , ... December 05, 2016 ... ... security executive networking and relationship-marketing firm, announced today that nominations will be ... Information Security Executive® (ISE®) Central Awards. , Awards include the Information Security ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Pa. , Dec. 5, 2016  Pennsylvania Physician ... Drug and Alcohol Programs Gary Tennis today ... drug, at Minnich,s Pharmacy in York ... order signed by Dr. Levine as a prescription to ... "It,s important to remember that any Pennsylvanian ...
(Date:12/5/2016)... India , December 5, 2016 According ... by Treatment modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free ... published by MarketsandMarkets, the market is projected to reach USD 779.8 ... a CAGR of 13.5% during the forecast period of 2016 to ... ...
(Date:12/5/2016)... Sanovas, Inc., a life science asset holding company ... wholly owned subsidiary, Intubation Science, Inc., and its LightSpeed Intubation ... http://photos.prnewswire.com/prnh/20161202/445251LOGO   ... Sanovas, Inc. ... There are over 40 million Endotracheal Intubations performed annually ...
Breaking Medicine Technology: